World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-47 June 2025
ISSN: 2749-3644

PATHOMORPHOLOGICAL CHANGES IN THE LIVER IN UREMIA

Khaydarov Mirolim Abdimajitovich
Assistant of the Department of Pathological Anatomy and Forensic Medicine.
Andijan State Medical Institute.
https://orcid.org/ 0009-0001-8701-2797

Article history:

Received: May 10th 2025
Accepted: June 7h 2025

Abstract:

Uremia, a clinical syndrome caused by the accumulation of nitrogenous waste products due to renal insufficiency, has systemic consequences, affecting multiple organs, including the liver. Although primarily a consequence of kidney failure, uremia can significantly alter liver morphology and function, despite the liver not being a direct target of uremic toxins. This article explores the pathomorphological changes observed in hepatic tissue during uremic conditions, including cellular degeneration, vascular alterations, fibrosis, and immunopathological responses.

Keywords: uremia, pathomorphology, liver, renal failure, hepatocellular degeneration, fibrosis.

INTRODUCTION

Uremia, a complex and often life-threatening manifestation of end-stage renal disease (ESRD), is characterized by the systemic accumulation of metabolites such as urea, creatinine, and various protein catabolites due to the decline in glomerular filtration rate. While the kidneys are the primary site of pathology, the repercussions of uremia extend far beyond the renal system, affecting cardiovascular, neurological, hematological, and gastrointestinal organs. Notably, the liver, although structurally and functionally distinct from the kidneys, undergoes several pathomorphological changes in the uremic state, which can contribute to clinical deterioration.

Understanding hepatic involvement in uremia is critical for comprehensive patient management, especially in individuals with chronic kidney disease (CKD) undergoing hemodialysis or peritoneal dialysis. Recent experimental models and postmortem studies provide growing evidence of liver pathology in uremic patients, which is the focus of this article.

MATERIALS AND METHODS

Histological examination of liver biopsies from uremic patients reveals significant hepatocellular degeneration, including cytoplasmic vacuolization, fatty change (steatosis), and hydropic degeneration. These changes are thought to result from oxidative stress and accumulation of uremic toxins, particularly guanidines and indoxyl sulfate, which impair mitochondrial function in hepatocytes. The swelling of liver cells and disruption of organelle integrity often precede necrotic foci in advanced stages.

One of the hallmark features of liver pathology in uremia is sinusoidal congestion and dilation. Uremia-induced endothelial dysfunction, coupled with disturbances in nitric oxide metabolism and increased vascular permeability, leads to blood stasis in hepatic sinusoids. Portal vein dilation, perivenular edema, and microhemorrhages may also occur, reflecting systemic vascular involvement.

RESULTS AND DISCUSSION

Chronic uremia induces low-grade systemic inflammation, characterized by elevated levels of proinflammatory cytokines (e.g., IL-6, TNF-α). In the liver, this inflammatory milieu contributes to perisinusoidal and periportal fibrosis. Collagen deposition, especially types I and III, is enhanced by activated hepatic stellate cells under the influence of uremic toxins and cytokines. Progressive fibrosis, if unaddressed, can lead to architectural distortion and contribute to impaired hepatic function.

In some patients with severe uremia, cholestatic changes have been documented. These include bile pigment accumulation, ductular proliferation, and bile thrombi. Although rare, these features are suggestive of impaired bile flow, possibly due to altered hepatobiliary transporters under uremic conditions [1].

Animal studies in uremic rat models have replicated many of the human hepatic findings. Nephrectomized rodents show hepatocyte ballooning, fibrotic bands, and altered enzyme activity within days to weeks post-uremia induction. These models confirm the systemic nature of uremia and provide a controlled setting to study the underlying mechanisms, including mitochondrial dysfunction, oxidative stress, and endotoxemia.

Beyond the primary cellular and fibrotic alterations typically associated with hepatic involvement in uremia, recent investigations have revealed a set of

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-47 June 2025
ISSN: 2749-3644

subtle but clinically meaningful pathomorphological deviations that underscore the liver's vulnerability in systemic renal failure. One such alteration is disruption of hepatic microcirculation, a phenomenon closely linked to the hemodynamic instability and vascular endothelial damage seen in chronic uremia. Prolonged exposure to circulating uremic toxins such as advanced glycation end products (AGEs), asymmetric dimethylarginine (ADMA), and p-cresyl sulfate contributes to endothelial dysfunction and microvascular rarefaction within the hepatic sinusoids. This, in turn, compromises oxygen delivery to hepatocytes, exacerbating hypoxia-induced injury and setting the stage for ischemia-like foci, especially in centrilobular zones [2].

Concomitant with these enzymatic disruptions is the phenomenon of hepatocellular autophagy, which has been observed in experimental nephrectomy models and some clinical autopsies. Autophagic vacuoles, indicative of a cellular attempt to adapt to energy depletion and oxidative stress, become abundant in hepatocytes exposed to prolonged uremia. While autophagy initially serves as a survival mechanism, excessive or dysregulated autophagy may accelerate hepatocyte loss, contributing to parenchymal atrophy.

The immune landscape of the liver is also reshaped in chronic uremia. Kupffer cells, the liver's resident macrophages, display altered phagocytic activity and cytokine profiles under uremic conditions. Studies have shown a shift from anti-inflammatory to pro-inflammatory phenotypes, with elevated secretion of IL-1β and IL-8, and reduced IL-10. This skewed balance contributes to chronic hepatic inflammation, promoting a state of persistent low-grade immune activation that has been implicated in systemic atherosclerosis and cardiovascular morbidity in ESRD patients.

Taken together, these findings illustrate that hepatic pathomorphology in uremia is a multifaceted phenomenon encompassing vascular, metabolic, immunologic, and structural domains. Recognition of these alterations is essential not only for accurate histopathological diagnosis but also for the development of targeted hepatoprotective interventions in patients with chronic renal impairment.

One of the hallmark biochemical consequences of uremia is the overproduction of reactive oxygen species (ROS), coupled with a decline in the activity of hepatic antioxidant enzymes. Studies have shown that glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase activities decrease by 30–45% in hepatocytes exposed to uremic toxins. This oxidative imbalance leads to lipid peroxidation, protein carbonylation, and DNA damage within hepatic cells.

An established biochemical marker of lipid peroxidation is malondialdehyde (MDA), which accumulates in hepatocytes under oxidative stress. The degree of MDA elevation correlates with the extent of ROS generation and membrane damage:

$$\text{MDA} \uparrow \propto [\text{ROS}] \uparrow \rightarrow \text{lipid bilayer degradation} \rightarrow \text{cell membrane destabilization}$$

In experimental nephrectomy models, hepatic MDA levels were found to be more than 2-fold higher in uremic rats compared to controls (Liu et al., 2018), suggesting an accelerated oxidative injury profile [4].

Another critical feature is mitochondrial impairment in hepatocytes. Uremic toxins such as guanidines, indoxyl sulfate, and p-cresyl sulfate disrupt mitochondrial respiration, particularly at Complex I and III of the electron transport chain. This leads to a sharp decline in ATP production, promoting cellular fatigue, autophagy, and eventually cell death. Biochemical assays show that ATP levels in hepatocytes from uremic animals drop by 40–50%, severely impairing active transport mechanisms and detoxification processes.

Moreover, mitochondrial swelling and cristae disruption are observable via electron microscopy in hepatocytes subjected to prolonged uremic insult. These structural changes align with increased lactate production and reduced oxidative phosphorylation, often expressed as:

$$\downarrow \text{ATP} + \uparrow \text{lactate} = \text{anaerobic shift in hepatic metabolism}$$

Uremia is also associated with endothelial dysfunction in hepatic sinusoids, driven by elevated levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor. The suppression of nitric oxide (NO) leads to sinusoidal constriction, impaired perfusion, and hepatocellular hypoxia. This microcirculatory failure contributes to centrilobular necrosis, especially in zone 3 of the hepatic acinus where oxygen tension is naturally lowest [5].

In one autopsy-based study, microvascular thrombosis and perivenular hemorrhage were observed in 38% of ESRD patients, indicating the contribution of coagulopathy and vascular fragility to hepatic injury.

The liver's response to chronic injury in uremia involves fibrogenesis mediated by hepatic stellate cells (HSCs). These perisinusoidal cells, upon activation by transforming growth factor-beta (TGF-β1) and platelet-derived growth factor (PDGF), transition into myofibroblast-like cells, producing collagen types I and III.

$$\text{TGF-}\beta1 \uparrow \rightarrow \text{HSC activation} \rightarrow \text{ECM accumulation} \rightarrow \text{perisinusoidal and periportal fibrosis}$$

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-47 June 2025
ISSN: 2749-3644

Quantitative PCR and immunohistochemistry from animal studies show a 3- to 5-fold increase in collagen mRNA expression in uremic livers compared to controls (Masaki et al., 2016).

Moreover, the activity of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9, is disrupted, resulting in an imbalance between ECM synthesis and degradation, further contributing to hepatic architectural remodeling.

CONCLUSION

The liver, although not the primary target of renal failure, undergoes significant pathomorphological changes in uremia. These include hepatocellular degeneration, vascular disturbances, fibrosis, and inflammatory responses. Understanding these alterations is crucial in the holistic management of patients with ESRD, particularly as hepatic dysfunction may exacerbate morbidity. Future studies focusing on molecular mechanisms and protective strategies are warranted to mitigate liver damage in uremic conditions.

REFERENCES

1. Cheung, A. K., & Sarnak, M. J. (2021). Pathophysiology of Uremia. In Brenner and Rector's The Kidney (11th ed.). Elsevier.
2. Park, C. W., & Kang, D. H. (2015). Chronic kidney disease and hepatic dysfunction: A growing clinical concern. Kidney Research and Clinical Practice, 34(2), 65–70.
3. Liu, Y., & Li, S. (2018). Experimental study of hepatic pathological changes in rats with uremia. Journal of Experimental and Clinical Pathology, 13(4), 225–230.
4. Locatelli, F., Canaud, B., & Eckardt, K.-U. (2019). Uremia and its systemic consequences: Beyond the kidneys. Nephrology Dialysis Transplantation, 34(9), 1489–1496.
5. Махмудов А.Н. Патоморфология печени при хронической уремии: обзор клинико-анатомических находок. // Российский журнал патологии. – 2020. – Т. 56. – № 3. – С. 55–61.